TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01293812
Drug: placebo po
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated).
Study: NCT02701205
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
Study: NCT01646814
Drug: PL2200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL2200, containing 325 mg aspirin active ingredient
Study: NCT00326443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffer placebo administered on Day 0.
Study: NCT04335071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
Study: NCT03666988
Drug: GSK3368715
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
Study: NCT03666988
Drug: GSK3368715
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
Study: NCT02708680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pill containing no active drug ingredient
Study: NCT01384851
Drug: Refresh Dry Eye Therapy
Normalized name: Refresh Dry Eye Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop both eyes four times daily for two weeks
Study: NCT04390399
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT04390399
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study: NCT02294032
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care for patients post-transplant
Study: NCT04326790
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment
Study: NCT00659841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03532022
Drug: Chronocort®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
Study: NCT03532022
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
Study: NCT01478022
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg daily, capsules
Study: NCT00806260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 4 weeks
Study: NCT02171689
Drug: [14C]- BIBW 2992 MA2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Study: NCT03111316
Drug: Cervidil 10 MG Vaginal Insert
Normalized name: Cervidil 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
Study: NCT01677871
Drug: 2HRZE/4HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
Study: NCT01677871
Drug: 2HRLE/4HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
Study: NCT02057926
Drug: The effect of tetracycline in degradation and permeability of collagen membranes.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03333694
Drug: Cutaneous Cream application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous Cream application twice daily with experimental (CLL442)
Study: NCT03333694
Drug: Placebo Cutaneous Cream application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous Cream application twice daily with placebo
Study: NCT03654274
Drug: Estradiol/norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
Study: NCT02701764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01938261
Drug: 0.45 % saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03761056
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to package insert
Study: NCT01679483
Drug: FloSeal application
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
Study: NCT04459416
Drug: opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.
Study: NCT03521700
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L.
Study: NCT01576783
Drug: Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DHA+ 200 mg AA per day for 6 months
Study: NCT01082848
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD during 26 weeks
Study: NCT01819272
Drug: Met DR
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin delayed-release tablets
Study: NCT01819272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo delayed-release tablets
Study: NCT01887405
Drug: Adrenaline auto-injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water
Study: NCT02022709
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Study: NCT01856322
Drug: Sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tablet 150mg twice daily
Study: NCT01856322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet twice daily
Study: NCT02359006
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline will be compared with placebo
Study: NCT02359006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be compared with minocycline
Study: NCT00002493
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00830050
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg BID 7 days
Study: NCT00830050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID 7 days
Study: NCT01868828
Drug: PAD
Normalized name: PAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Therapy of PAD for 4 cycles.
Study: NCT01868828
Drug: VCD
Normalized name: STATLOCK PICC,VCDC ANCHOR DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Therapy of VCD for 4 cycles.
Study: NCT00551096
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
Study: NCT00551096
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
Study: NCT03376932
Drug: FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
Study: NCT03376932
Drug: FP/SAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
Study: NCT00800800
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg, oral, single dose
Study: NCT00800800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, single dose
Study: NCT02572375
Drug: Codeine Phosphate/Guaifenesin ER Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
Study: NCT02572375
Drug: Codeine Phosphate/Guaifenesin IR Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
Study: NCT01345448
Drug: Placebo Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lotion dosed once.
Study: NCT00005852
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00392093
Drug: Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01642550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01971684
Drug: Second Line ITP agents
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treating physicians will select the second line agent and clinical data will be collected.
Study: NCT01923766
Drug: Cytotoxic T lymphocytes (CTLs).
Approvals — FDA: no, EMA: no, PMDA: no
Description: This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated.
Study: NCT01162551
Drug: Sirolimus and Methotrexate
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days.
Study: NCT01336244
Drug: GLPG0778
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules containing 50 or 100 mg of GLPG0778
Study: NCT01336244
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
Study: NCT00039013
Drug: AC2993
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT00039013
Drug: AC2993
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT00039013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT00039013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT00308334
Drug: Placebo- Sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo po TID x 14 days
Study: NCT00532844
Drug: Sapropterin Dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
Study: NCT00532844
Drug: Sapropterin Dihydrochloride and Vitamin C
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
Study: NCT01382771
Drug: Intra-articular corticosteroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
Study: NCT01382771
Drug: Intra-articular saline injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 0.5 cc normal saline in each joint
Study: NCT00335166
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00997789
Drug: Rebamide
Normalized name: benzocaine / trimethobenzamide hydrochloride Rectal Suppository [Tebamide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide 100 mg Tablet, three times a day
Study: NCT03278548
Drug: Volulyte 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT03278548
Drug: Ionolyte
Normalized name: Isolyte H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT04419467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT03132558
Drug: Radiopaque Media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01366573
Drug: GSK1521498
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
Study: NCT01602341
Drug: AN2728 Topical Ointment, 0.5% BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2728 Topical Ointment, 0.5% BID
Study: NCT00295646
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg q6m
Study: NCT03175731
Drug: Proton Pump Inhibitors
Normalized name: Proton pump inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Study: NCT03175731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Study: NCT02138812
Drug: BAY1161909
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
Study: NCT00720577
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 Mg. tablet, 1 tablet daily
Study: NCT02377557
Drug: Topical Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02099825
Drug: d-cycloserine and mifepristone
Normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
Study: NCT04078204
Drug: placebo Soft Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
Study: NCT04067531
Drug: treatment of BV with first Deqularum and then direkt after with vaginal clindamycin
Normalized name: vaginal ring with progestogen and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will get the same treatment
Study: NCT02855658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Study: NCT00447967
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
Study: NCT00447967
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
Study: NCT01822665
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Liquid gelation capsules or tablets of 400 mg strength
Study: NCT01828840
Drug: epidural fentanyl via PCEA
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03924804
Drug: Ringer's solution acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
Study: NCT03924804
Drug: Ringer's solution acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
Study: NCT03924804
Drug: Ringer's solution acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
Study: NCT04672135
Drug: REM0046127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution: 100 mg/mL REM0046127
Study: NCT04672135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution with 0 mg/mL REM0046127
Study: NCT01991483
Drug: LY2928057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT01991483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04314817
Drug: Any drug used to treat Covid-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
Study: NCT00551889
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00551889
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01070979
Drug: Estradiol acetate
Normalized name: Estradiol Acetate
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet containing 0.9 mg E3A, daily oral administration.
Study: NCT01070979
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet containing 1 mg estradiol, daily oral administration.
Study: NCT01474304
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
Study: NCT00137059
Drug: acetaminophen sustained-release
Normalized name: acetaminophen Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00876252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl